Production was located in Norway, Denmark, Poland, Austria, Belgium, Germany, Estonia, India, Mexico, Brazil and Argentina.

The company awarded an annual prize totaling 20,000 euros to four excellent junior scientists at the University of Konstanz.

In 1969, the revolutionary radiocontrast agent Amipaque was discovered, starting a long process of internationalisation.

The closing deal was completed on 21 February 2008, and Bradley Pharmaceuticals became an integral part of Nycomed.

Nycomed pursued a strategy of licensing new medicines from research companies and introducing them to Europe.

[3] By 2011, Nycomed was a privately-held Swiss company; that year Takeda Pharmaceuticals, Japan's biggest drugmaker, bought most of the company for about $14 billion - the deal did not include Nycomed's US dermatology business.

[4] That deal made Takeda the world's 12th biggest drugmaker, which in January 2012, said it would cut about 10% of its workforce by reducing the number of people it employed outside Japan by 2,800 as it sought to 'streamline its global operations after its acquisition of Nycomed', a purchase that had dented its 2011-2012 profit by 31% [5] In addition to internal research and development activities, Nycomed was also involved in publicly funded collaborative research projects with other industrial and academic partners.